Page last updated: 2024-11-06

1-n-butylimidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-n-Butylimidazole is a derivative of imidazole, a heterocyclic aromatic organic compound. It has been studied for its potential applications in various fields, including catalysis, pharmaceuticals, and materials science. The compound exhibits a strong basic character due to the nitrogen atoms in the imidazole ring, making it a useful catalyst for various chemical reactions. Research has explored its use in the synthesis of organic compounds, such as polymers and pharmaceuticals, as well as its ability to promote the formation of specific functional groups. The compound is also being investigated for its potential biological activities, including antibacterial and antifungal properties. '

Cross-References

ID SourceID
PubMed CID61347
CHEMBL ID97667
SCHEMBL ID81565
MeSH IDM0101566

Synonyms (37)

Synonym
bdbm36010
1-subsituted 1h-imidazole, 2
CHEMBL97667
1h-imidazole, 1-butyl-
1-butyl-1h-imidazole
nsc-158165
4316-42-1
nsc158165
inchi=1/c7h12n2/c1-2-3-5-9-6-4-8-7-9/h4,6-7h,2-3,5h2,1h
1-butylimidazole, 98%
B2345
1-butylimidazole
AKOS000118804
A15568
1-butyl-1h-imidazole;n-butylimidazole
n-butylimidazole
un2690
nsc 158165
c7jxc99e8f ,
n-n-butyl imidazole [un2690] [poison]
n-n-butyl imidazole
unii-c7jxc99e8f
1-n-butylimidazole
einecs 224-335-9
n-(n-butyl)imidazole
FT-0607563
SCHEMBL81565
n-n-butylimidazole
W-106244
un 2690
imidazole, 1-butyl-
mfcd00042753
DTXSID8073976
AS-12411
BCP27242
D95315
EN300-19489
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2A6Homo sapiens (human)IC50 (µMol)65.00000.00443.889510.0000AID1799628
Cytochrome P450 2A13Homo sapiens (human)IC50 (µMol)65.00006.20006.20006.2000AID1799628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCytochrome P450 2A6Homo sapiens (human)
steroid metabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2A6Homo sapiens (human)
coumarin catabolic processCytochrome P450 2A6Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2A13Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 2A13Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2A13Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2A13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
iron ion bindingCytochrome P450 2A6Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A6Homo sapiens (human)
enzyme bindingCytochrome P450 2A6Homo sapiens (human)
heme bindingCytochrome P450 2A6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A6Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A6Homo sapiens (human)
monooxygenase activityCytochrome P450 2A13Homo sapiens (human)
iron ion bindingCytochrome P450 2A13Homo sapiens (human)
coumarin 7-hydroxylase activityCytochrome P450 2A13Homo sapiens (human)
heme bindingCytochrome P450 2A13Homo sapiens (human)
aromatase activityCytochrome P450 2A13Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2A13Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2A13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 2A6Homo sapiens (human)
cytoplasmic microtubuleCytochrome P450 2A6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A6Homo sapiens (human)
cytoplasmCytochrome P450 2A6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2A13Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2A13Homo sapiens (human)
cytoplasmCytochrome P450 2A13Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID69601Minimum bacterial concentration (MBC) against Escherichia coli2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis of N-alkylated derivatives of imidazole as antibacterial agents.
AID207688Minimum inhibitory concentration (MIC) against Staphylococcus aureus2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis of N-alkylated derivatives of imidazole as antibacterial agents.
AID164233Minimum bacterial concentration (MBC) against Pseudomonas aeruginosa2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis of N-alkylated derivatives of imidazole as antibacterial agents.
AID162932Minimum inhibitory concentration (MIC) against Pseudomonas aeruginosa2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis of N-alkylated derivatives of imidazole as antibacterial agents.
AID69197Minimum inhibitory concentration (MIC) against Escherichia coli2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis of N-alkylated derivatives of imidazole as antibacterial agents.
AID206851Minimum bacterial concentration (MBC) against Staphylococcus aureus2003Bioorganic & medicinal chemistry letters, Sep-01, Volume: 13, Issue:17
Synthesis of N-alkylated derivatives of imidazole as antibacterial agents.
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID1799628Inhibition Assay from Article 10.1002/cbic.200800712: \\Synthesis and in vitro activity of heterocyclic inhibitors of CYP2A6 and CYP2A13, two cytochrome P450 enzymes present in the respiratory tract.\\2009Chembiochem : a European journal of chemical biology, Jun-15, Volume: 10, Issue:9
Synthesis and in vitro activity of heterocyclic inhibitors of CYP2A6 and CYP2A13, two cytochrome P450 enzymes present in the respiratory tract.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's5 (71.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.82

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.82 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.14 (4.65)
Search Engine Demand Index19.78 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.82)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]